SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report)’s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $8.87 and traded as high as $24.89. SELLAS Life Sciences Group shares last traded at $19.15, with a volume of 119,833,416 shares.
Key Stories Impacting SELLAS Life Sciences Group
These are some of the SLS stories that stood out recently:
- Positive Sentiment: The offering is expected to raise $150 million in gross proceeds, giving SELLAS additional funding to advance its cancer-drug development programs, including GPS and SLS009. Underwriters also have an option to buy up to 1.73 million more shares. SELLAS offering announcement
- Negative Sentiment: SELLAS priced 11.54 million new shares at $13 each, a discount to the prevailing market price. The added shares dilute existing shareholders, and the discounted offering price may weigh on the stock as the deal closes. SELLAS prices public offering
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.
Read Our Latest Analysis on SELLAS Life Sciences Group
SELLAS Life Sciences Group Stock Down 17.2%
The stock has a market cap of $3.03 billion, a price-to-earnings ratio of -74.30 and a beta of 2.73. The business’s 50 day simple moving average is $11.11 and its 200 day simple moving average is $8.99.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05).
Hedge Funds Weigh In On SELLAS Life Sciences Group
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp raised its stake in SELLAS Life Sciences Group by 86.6% in the 1st quarter. Bank of New York Mellon Corp now owns 478,366 shares of the company’s stock valued at $2,023,000 after acquiring an additional 221,957 shares during the period. Bank of America Corp DE lifted its holdings in SELLAS Life Sciences Group by 535.7% during the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock valued at $2,714,000 after purchasing an additional 540,748 shares during the last quarter. Dagco Inc. boosted its position in SELLAS Life Sciences Group by 19.8% during the second quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock worth $18,191,000 after purchasing an additional 203,653 shares during the period. Wellington Management Group LLP boosted its position in SELLAS Life Sciences Group by 73.2% during the second quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock worth $8,816,000 after purchasing an additional 252,531 shares during the period. Finally, Quantinno Capital Management LP bought a new position in SELLAS Life Sciences Group during the first quarter worth $315,000. Institutional investors own 17.38% of the company’s stock.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
See Also
- Five stocks we like better than SELLAS Life Sciences Group
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
